fascin actin-bundling protein 1Genealiases: HSN · SNL · p55
Q-omics provides the consensus-scored FSCN1 profile across patient tissues and cancer cell-line models. FSCN1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FSCN1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FSCN1 protein abundance shows 22,230 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, and HNSC as cancer lineages where FSCN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FSCN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FSCN1 survival associations across molecular data types. FSCN1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FSCN1 RNA expression–survival associations across cancer types. High FSCN1 expression shows unfavorable associations in ACC, MESO, HNSC, LUAD, THCA and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FSCN1 RNA expression.
This table summarizes FSCN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FSCN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FSCN1 shows higher tumor expression in HNSC, KIRC, COAD, LUAD, BLCA and STAD. The HNSC box plot shows higher FSCN1 RNA expression in tumor versus normal tissue (log2 FC = +2.816, t-test p < 0.001).
This table shows molecular features associated with FSCN1 in patient tissues and cancer cell lines. In patient samples, FSCN1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, FSCN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
